Table of Contents PART 01: Executive summary • Alternate therapies hinder the growth possibilities of approved therapies PART 02: Scope of the report • Market overview • Assumptions • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Highlights PART 05: Market landscape • Market overview • Five forces analysis PART 06: Market segmentation by product type • Global mAbs market • Global human insulin market • Global clotting factors market • Global EPO market • Global human growth hormone market PART 07: Market segmentation by therapy area • Metabolic and endocrine disorders • Hematopoiesis • Fertility • Cancer • Autoimmune diseases • Infectious diseases • Protein vaccine PART 08: Market segmentation by protein function • Enzymatic and regulatory activity • Special targeting activity • Vaccines • Protein diagnostics PART 09: Geographical segmentation • Protein therapeutics market in Americas • Protein therapeutics market in EMEA • Protein therapeutics market in APAC PART 10: Market drivers • Increased demand for mAbs • Development of novel therapies using innovative technologies • Availability of favorable reimbursement policies PART 11: Impact of drivers PART 12: Market challenges • Complexities in manufacturing, storage conditions, distribution policies, and high cost • Complicated regulatory framework • Alternate therapies loom large PART 13: Impact of drivers and challenges PART 14: Market trends • Emergence of next-generation biologics • Advent of biosimilars expected to improve the treatment rates • Strategic alliances further boost the R&D efforts PART 15: Vendor landscape • Competitive scenario • Market share analysis 2016 • Other prominent vendors PART 16: Key vendor analysis • F. Hoffmann-La Roche • Novo Nordisk • Amgen • AbbVie • Johnson & Johnson • Merck PART 17: Appendix • List of abbreviations PART 18: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Overview of protein therapeutics market 2016-2021 Exhibit 03: Key strategies in global protein therapeutics market Exhibit 04: Global protein therapeutics market snapshot: Developed and emerging markets 2015 Exhibit 05: Global protein therapeutics market 2016-2021 ($ billions) Exhibit 06: Patent expirations of major biologics 2000-2030 Exhibit 07: Impact of factors affecting the market 2016 and 2021 Exhibit 08: Five forces analysis Exhibit 09: Segmentation of global protein therapeutics market by product type Exhibit 10: Market share of global protein therapeutics market by product type Exhibit 11: Overview of global mAbs market Exhibit 12: Annual treatment cost per patient for various drugs 2015 Exhibit 13: Global mAbs market: Present and future scenario Exhibit 14: Global mAbs market 2016-2021 ($ billions) Exhibit 15: Opportunity analysis of global mAbs market Exhibit 16: Year-over-year (YoY) sales comparison of mAbs 2013-2015 ($ billions) Exhibit 17: Market overview of human insulin Exhibit 18: Global human insulin market 2016-2021 ($ billions) Exhibit 19: Factors affecting global human insulin market Exhibit 20: Opportunity analysis of global human insulin market Exhibit 21: Revenues from the sales of top five products in insulin market 2013-2015 ($ billions) Exhibit 22: Market overview of clotting factors Exhibit 23: Global clotting factors market 2016-2021 ($ billions) Exhibit 24: Opportunity analysis of global clotting factors market Exhibit 25: Market overview of EPO Exhibit 26: Global EPO market 2016-2021 ($ billions) Exhibit 27: Globally approved EPO biosimilars Exhibit 28: Opportunity analysis of global EPO market Exhibit 29: Market overview of human growth hormone Exhibit 30: Global human growth hormone market 2016-2021 ($ billions) Exhibit 31: Opportunity analysis of global human growth hormone market Exhibit 32: Segmentation of global protein therapeutics market by therapy area Exhibit 33: Segmentation of global protein therapeutics market by protein function Exhibit 34: Global protein therapeutics market: Segmentation by geography (2016-2021) Exhibit 35: Global protein therapeutics market segmentation by region: Market growth lifecycle analysis 2016 Exhibit 36: Overview of protein therapeutics market in Americas Exhibit 37: Protein therapeutics market in Americas 2016-2021 ($ billions) Exhibit 38: Protein therapeutics market in Americas: Opportunity analysis Exhibit 39: Overview of protein therapeutics market in EMEA Exhibit 40: Protein therapeutics market in EMEA 2016-2021 ($ billions) Exhibit 41: Protein therapeutics market in EMEA: Opportunity analysis Exhibit 42: Overview of protein therapeutics market in APAC Exhibit 43: Protein therapeutics market in APAC 2016-2021 ($ billions) Exhibit 44: Protein therapeutics market in APAC: Opportunity analysis Exhibit 45: mAb approvals by the US FDA and EMA 2010-2015 Exhibit 46: Advances in ADCs technology Exhibit 47: Few of other technologies used in protein therapeutics Exhibit 48: Impact of drivers Exhibit 49: Approval process of biologicals versus biosimilars via Public Health Service Act (PHSA) in US Exhibit 50: Few of CAM therapies used for autoimmune and inflammatory diseases Exhibit 51: Impact of drivers and challenges Exhibit 52: Overview of next-generation antibodies Exhibit 53: Oral insulin pipeline portfolio Exhibit 54: Few of the biosimilars under development Exhibit 55: Key deals in global protein therapeutics market Exhibit 56: Market presence of vendors in various therapy areas 2015 Exhibit 57: Competitive assessment of vendors Exhibit 58: Geographical presence of key vendors Exhibit 59: F. Hoffmann-La Roche: Profile Exhibit 60: F. Hoffmann-La Roche: Strength assessment Exhibit 61: F. Hoffmann-La Roche: Strategy assessment Exhibit 62: F. Hoffmann-La Roche: Opportunity assessment Exhibit 63: Novo Nordisk: Profile Exhibit 64: Novo Nordisk: Strength assessment Exhibit 65: Novo Nordisk: Strategy assessment Exhibit 66: Novo Nordisk: Opportunity assessment Exhibit 67: Amgen: Profile Exhibit 68: Amgen: Strength assessment Exhibit 69: Amgen strategy assessment Exhibit 70: Amgen: Opportunity assessment Exhibit 71: AbbVie: Profile Exhibit 72: AbbVie: Strength assessment Exhibit 73: AbbVie: Strategy assessment Exhibit 74: AbbVie: Opportunity assessment Exhibit 75: Johnson & Johnson: Profile Exhibit 76: Johnson & Johnson: Strength assessment Exhibit 77: Johnson & Johnson: Strategy assessment Exhibit 78: Johnson & Johnson: Opportunity assessment Exhibit 79: Merck: Profile Exhibit 80: Merck: Strength assessment Exhibit 81: Merck: Strategy assessment Exhibit 82: Merck: Opportunity assessment

AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Merck, Novo Nordisk, Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, BioGenomics, Biopartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, MacroGenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, XOMA.